# JP Morgan Healthcare Conference A New Era of Pfizer R&D Productivity



Mikael Dolsten, M.D., Ph.D. President, Worldwide R&D January 8, 2018

### Forward-Looking Statements

This presentation includes forward-looking statements about, among other things, our in-line products and product candidates, including anticipated regulatory submissions, data read-outs, approvals, performance, timing of exclusivity, potential benefits of Pfizer's products and product candidates, and anticipated future operating and financial performance that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. The forward-looking statements in this presentation speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.



# Step Change in Pfizer R&D Productivity Actual and potential blockbuster approvals (as of January 2018)

### Up to 15 in 5 Years\*



Oncology



Inflammation & immunology



**Vaccines** 





Rare Disease & Internal Med

2017-2022

Return to Growth

Prevnar 13
Pneumococci | 3 volent Conjugate Vaccine (Adult)
(Dichtherio CRIII... Protein)

apixaban XELJANZ

eucrisa."

Eliguis.

IBRANCE)



2005-2010

**Pre/Early** Wyeth

R&D **Transformation** 

2011-2016



- IO-Targeted / IO-Chemo
- Targeted Cancer Agents (Collective) (talazoparib, lorlatinib, dacomitinib, glasdegib)
- Ibrance® Intermediate/High Risk eBC
- Xtandi® non meta. PROSPER/EMBARK
- **JAK1 Atopic Dermatitis**
- JAK 'X' Alopecia/Vitiligo
- Xeljanz LCM
- Clostridium Difficile
- 10. Staphylococcus Aureus
- 11. Pneumococcal Nextgen
- 12. domagrozumab Duchenne
- 13. rivipansel Sickle Cell
- 14. tafamidis Cardiomyopathy
- 15. tanezumab Pain

\*Subject to attrition

Note: Examples reflect when cumulative Peak Year Sales are anticipated to exceed \$1B.



#### Potential 2018 Milestones

#### LATE STAGE

Xtandi® nmCRPC PROSPER Submission (US/EU) talazoparib
EMBRACA
Submission (US/EU)

Xeljanz®
Ulcerative Colitis
Action Date (US/EU)

Iorlatinib
NSCLC 2L
Action Date (US)

Bavencio® NSCLC 2L Phase 3 Data Vyndaqel®
Cardiomyopathy
Phase 3 Data

rivipansel Sickle Cell Phase 3 Data tanezumab
OA/CLBP Pain
Phase 3 Data

1H **2018** 

2H **2018** 

Ibrance® Combo
PDAC
Phase 1 Data

TFPI mAb
Hemophilia
Phase 1b/2 Data

Selective JAK's

Alopecia, Psoriasis

Phase 2 Data

Bavencio® Triplet + 4-1BB + OX-40 Phase 1 Data

JAK3 Rheumatoid Arthritis Phase 1 Data Anti IL-33
Atopic Derm
Phase 1 Data

PNG 20, GBS, VBIR1
Vaccines
Phase 1 & 2 Data

ACC, FK, GLP1 NASH Phase 1 & 2 Data

#### **EARLY STAGE**



## Discussion

